Valeant Pharmaceuticals International
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Valeant Pharmaceuticals International's revenues will grow 37.8% and EPS will grow 28.7%.
The average estimate for revenue is $948.4 million. On the bottom line, the average EPS estimate is $1.21.
Last quarter, Valeant Pharmaceuticals International reported revenue of $884.1 million. GAAP reported sales were 47% higher than the prior-year quarter's $600.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.15. GAAP EPS of $0.02 for Q3 were 85% lower than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 74.0%, 160 basis points better than the prior-year quarter. Operating margin was 25.8%, 170 basis points better than the prior-year quarter. Net margin was 0.9%, 590 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $3.50 billion. The average EPS estimate is $4.41.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 194 members out of 219 rating the stock outperform, and 25 members rating it underperform. Among 74 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 67 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $65.38.
- Add Valeant Pharmaceuticals International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.